The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
Open accessAbstract
We recently reported that BRAF V600E is the principal oncogenic driver of papillary craniopharyngioma, a highly morbid intracranial tumor commonly refractory to treatment. Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150mg, orally twice daily) and trametinib (2mg, orally twice daily). After 35 days of treatment, tumor volume was reduced by 85%. Mutations that commonly mediate resistance to MAPK pathway inhibition were not detected in a post-treatment sample by whole exome sequencing. A blood-based BRAF V600E assay detected circulating BRAF V600E in the patient's blood. Re-evaluation of the existing management paradigms for craniopharyngioma is warranted, as patient morbidity might be reduced by noninvasive mutation testing and neoadjuvant-targeted treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Self-citationDolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up
Karavitaki, N., Brufani, C., Warner, J. T., Adams, C. B. T., Richards, P., Ansorge, O., Shine, B., Turner, H. E., & Wass, J. A. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02231.x · Cited by 633
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
Brastianos, P. K., Taylor-Weiner, A., Manley, P. E., Jones, R. T., Dias-Santagata, D., Thorner, A. R., Lawrence, M. S., Rodriguez, F. J., Bernardo, L. A., Schubert, L., et al. (2014) · Nature Genetics · doi:10.1038/ng.2868 · Cited by 521
Self-citationAscierto, P. A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R. F., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8691 · Cited by 432
Papillary craniopharyngioma: a clinicopathological study of 48 cases
Crotty, T. B., Scheithauer, B. W., Young, W. F., Davis, D. H., Shaw, E. G., Miller, G. M., & Burger, P. C. (1995) · Journal of Neurosurgery · doi:10.3171/jns.1995.83.2.0206 · Cited by 302
Haroche, J., Cohen-Aubart, F., Emile, J.-F., Maksud, P., Drier, A., Tolédano, D., Barete, S., Charlotte, F., Cluzel, P., Donadieu, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1950 · Cited by 289
Cited by
Overview of the 2022 WHO Classification of Pituitary Tumors
Asa, S. L., Mete, O., Perry, A., & Osamura, R. Y. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09703-7 · Cited by 641
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550
Müller, H. L., Merchant, T. E., Warmuth-Metz, M., Martinez-Barbera, J.-P., & Puget, S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0125-9 · Cited by 515
Gritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N. (2022) · Cancer · doi:10.1002/cncr.33918 · Cited by 372
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Abedalthagafi, M., Bi, W. L., Aizer, A. A., Merrill, P. H., Brewster, R., Agarwalla, P. K., Listewnik, M. L., Dias-Santagata, D., Thorner, A. R., Van Hummelen, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov316 · Cited by 293
Self-citation
Metadata
- Authors
- Brastianos, P. K., Shankar, G. M., Gill, C. M., Taylor-Weiner, A., Nayyar, N., Panka, D. J., Sullivan, R. J., Frederick, D. T., Abedalthagafi, M., Jones, P. S., Dunn, I. F., Nahed, B. V., Romero, J. M., Louis, D. N., Getz, G., Cahill, D. P., Santagata, S., Curry, W. T., & Barker, F. G.
- Venue
- Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-10-23
- Volume
- 108
- Issue
- 2
- Pages
- djv310
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2208625206
- Cited by
- 258
- References
- 15
- FWCI
- 17.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. https://app.cochat.ai/papers/10.1093/jnci/djv310
- The paper
- Brastianos, P. K., Shankar, G. M., Gill, C. M., Taylor-Weiner, A., Nayyar, N., Panka, D. J., Sullivan, R. J., Frederick, D. T., Abedalthagafi, M., Jones, P. S., Dunn, I. F., Nahed, B. V., Romero, J. M., Louis, D. N., Getz, G., Cahill, D. P., Santagata, S., Curry, W. T., & Barker, F. G. (2016). Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djv310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.